Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
D.Western Therapeutics Institute ( (JP:4576) ) just unveiled an announcement.
D. Western Therapeutics Institute has announced the development of ‘H-1129’ as a new pipeline candidate for treating ocular surface diseases related to immune disorders, such as keratoconjunctival diseases. This strategic move aims to leverage the company’s existing intellectual property and expertise in kinase inhibitors, following the discontinuation of its development as a glaucoma treatment. The company plans to initiate clinical trials in fiscal year 2026, with no immediate impact on the current earnings forecast, although future revisions may be announced if necessary.
More about D.Western Therapeutics Institute
D. Western Therapeutics Institute, Inc. operates in the pharmaceutical industry, focusing on drug discovery and development. The company specializes in creating therapeutic agents, particularly protein kinase inhibitors, for various medical conditions.
Average Trading Volume: 872,508
Technical Sentiment Signal: Buy
Current Market Cap: Yen6.27B
Learn more about 4576 stock on TipRanks’ Stock Analysis page.